Steven P. Rowe, MD, PhD, Author at Grand Rounds in Urology

Panel Discussion: MRI and PSMA Discordance

Abhinav Sidana, MD, MPH, FACS, Steven P. Rowe, MD, PhD, Mark Emberton, MD, FRCS, Arvin K. George, MD and Sadhna M. Verma, MD, MBA, FSAR | Feb 2026

Experts discuss MRI and PSMA discordance, demonstrating how combined imaging enhances lesion evaluation.

Pitfalls of PSMA PET Imaging: False Positive, Equivocal, False Negative, Intraprostatic Uptake

Steven P. Rowe, MD, PhD | Feb 2026

Dr. Steven Rowe explains the pitfalls of PSMA PET imaging, including false positives, false negatives, tracer differences, and challenges with intraprostatic interpretation.

Radiopharmaceuticals in Advanced Prostate Cancer

Steven P. Rowe, MD, PhD | Jun 2025

Steven P. Rowe, MD, PhD, delves into the transformative potential and challenges of radioligand therapy in managing advanced prostate cancer. In this 21-minute presentation, Dr. Rowe emphasizes the excitement surrounding the efficacy and tolerability of agents like lutetium PSMA-617, contrasting them with harsher cytotoxic treatments. A nuanced discussion addresses pitfalls in PSMA PET imaging, highlighting false positives and underscoring the necessity of careful interpretation.

Toxicity management and manageable side effects are discussed. Innovations in imaging biomarkers and longitudinal PSMA PET imaging are positioned as tools to refine response assessment and personalize therapy.

Given differences in training and systemic constraints, challenges in translating European advancements to US practice are acknowledged. Further, Dr. Rowe critiques limitations in AI and radiomics applications for PET scans, highlighting the inability to characterize findings accurately. Ultimately, Dr. Rowe advocates integrating PSMA PET into clinical trials and enhancing therapy stratification to maximize patient benefit.

PET Scanning in Primary Detection of Prostate Cancer

Steven P. Rowe, MD, PhD | Dec 2024

Steven P. Rowe, MD, PhD, examines the current role of PSMA PET imaging in prostate cancer detection and management, emphasizing its strengths, limitations, and areas requiring further research.

Dr. Rowe asserts in this detailed 15-minute talk that PSMA PET excels in identifying metastatic sites and aiding metastasis-directed therapy. He references advanced trials, such as OSPREY and Lighthouse, revealing its utility’s nuances.

Much of the discussion underscores the need for caution in interpreting data on extra-prostatic extension, with Rowe questioning recent claims of PSMA PET’s superiority over MRI. Challenges in standardizing interpretation across different scoring systems, such as PIRADS and Primary Score, are addressed, suggesting the potential oversimplification of tumor categorization. The talk also introduces technological barriers inherent in PET imaging.

Practical insights are provided into PSMA PET’s use in clinical settings. The societal and financial implications of widespread PSMA PET adoption are highlighted, stressing the need for cost-effective implementation strategies.